参芪肌痿颗粒治疗重症肌无力的临床疗效研究
Journal: Frontiers of Chinese Medicine Research DOI: 10.32629/fcmr.v8i2.20949
Abstract
目的：评价参芪肌痿颗粒治疗重症肌无力(MG)的临床疗效与安全性。方法：选取20 22年1月- 2024年6月我院收治的60例MG患者,随机分为中药治疗组(n=30)和对照组(n=30)。对 照组采用常规西医治疗,中药治疗组在对照组治疗基础上加用参芪肌痿颗粒。分别于 治疗前、治疗1个月及3个月时,评估两组患者的中医证候积分和日常生活能力(MG- ADL)评分,比较临床显效率并进行亚组分析。结果：治疗1个月时,中药治疗组显效率 (63.33%)明显高于对照组(33.33%),差异有统计学意义(P0.05)。两组 患者治疗后MG- ADL评分均较治疗前显著下降(P0.05)。亚组分 析显示,不同年龄、性别、临床分型、病程及中医证型患者的显效率和MG- ADL评分改善均无统计学意义(P均>0.05)。研究期间,未观察到患者出现与药物有关 的不良反应。结论：参芪肌痿颗粒治疗可快速改善MG患者的中医证候,疗效不受临床 特征影响,且安全性良好。
Keywords
参芪肌痿颗粒；重症肌无力；临床疗效；中医证候；日常生活能力评分
Full Text
PDF - Viewed/Downloaded: 2 TimesReferences
[1] Chen J,Tian DC,Zhang C,et al.Incidence, mortality, and economic burden of myasthenia gravis in China:A nationwide population-based study.Lancet Reg Health West Pac.2020;5:100063.
[2] Harris L,Graham S,MacLachlan S,et al.A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis.BMC Neurol.2022;22(1):172.
[3] Yan J,Choi K,Fu P,et al.The real-world impact of corticosteroid- associated adverse events in myasthenia gravis:A patient-reported survey analysis.Cell Immunol.2025;411-412:104956.
[4] 黄延鹏,乔文军.复方黄杞汤治疗Ⅰ、Ⅱ型老年重症肌无力回顾性分析[J].辽宁中医药 大学学报,2024,26(2):159-162.
[5] 郭逸凡,杜妙,杨洁,等.健脾益肾举陷汤联合西药治疗重症肌无力的临床及免疫指标 的前瞻性研究[J].时珍国医国药,2024,35(8):1927-1931.
[6] 黄春华,王瑞奇,饶旺福,等.温肾益气法治疗重症肌无力临床效果研究[J].辽宁中医 杂志,2023,50(10):87-91.
[7] 中国免疫学会神经免疫分会.中国重症肌无力诊断和治疗指南(2020版)[J].中国神 经免疫学和神经病学杂志,2021,28(1):1-12.
[8] 郑筱萸,中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002:378- 383.
[9] 李宏烨,李慧菊,付志博,等.参芪肌痿颗粒治疗重症肌无力临床疗效观察[J].河北中 医,2020,42(7):1017-1020.
[10] Janssen MF,Dewilde S,Wolfe GI,et al.Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets.J Neurol Sci.2024;463:123135.
[11] 宋健,曾进浩,刘友章,等.国医大师邓铁涛从脾论治重症肌无力临床经验[J].陕西 中医,2022,43(12):1774-1777.
[12] 刘小斌.国医大师邓铁涛诊治重症肌无力经验的学术传承与发展[J].广州中医药大 学学报,2024,41(10):2518-2525.
[13] 张会永,冷锦红,谢伟峰,等.张静生治疗重症肌无力临证经验与用药分析[J].中华 中医药学刊,2020,38(12):27-30.
[14] Weng S,Huang L,Cai B,et al.Astragaloside IV ameliorates experimental autoimmune myasthenia gravis by regulating CD4 + T cells and altering gut microbiota.Chin Med.2023;18(1):97.
[15] He X,Li Y,Chen J,et al.Ginsenoside Rg1 Attenuates Muscle Atrophy in Hyperglycemic Conditions, Inactivity and Protein Deprivation Models via AKT/mTOR Pathway Activation.Curr Mol Med.2025.
[16] Ran P,Jiang F,Pan L,et al.Polysaccharide from Atractylodes macrocephala Koidz.alleviates pyrotinib-induced diarrhea through regulating cAMP/LKB1/AMPK/CFTR pathway and restoring gut microbiota and metabolites.Int J Biol Macromol.2025;308:142512.
[17] 沈洁,陈园园,董云,等.基于数据挖掘探讨中医药治疗眼肌型重症肌无力的用药规 律[J].中国中医药科技,2023,30(5):1034-1037.
[18]郑鸿铭,胡芝凡,黄梦芬,等.基于数据挖掘和网络药理学研究中药复方治疗重症肌无力的用药规律及作用机制[J].天津中医药,2024,41(3):372-385.
[2] Harris L,Graham S,MacLachlan S,et al.A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis.BMC Neurol.2022;22(1):172.
[3] Yan J,Choi K,Fu P,et al.The real-world impact of corticosteroid- associated adverse events in myasthenia gravis:A patient-reported survey analysis.Cell Immunol.2025;411-412:104956.
[4] 黄延鹏,乔文军.复方黄杞汤治疗Ⅰ、Ⅱ型老年重症肌无力回顾性分析[J].辽宁中医药 大学学报,2024,26(2):159-162.
[5] 郭逸凡,杜妙,杨洁,等.健脾益肾举陷汤联合西药治疗重症肌无力的临床及免疫指标 的前瞻性研究[J].时珍国医国药,2024,35(8):1927-1931.
[6] 黄春华,王瑞奇,饶旺福,等.温肾益气法治疗重症肌无力临床效果研究[J].辽宁中医 杂志,2023,50(10):87-91.
[7] 中国免疫学会神经免疫分会.中国重症肌无力诊断和治疗指南(2020版)[J].中国神 经免疫学和神经病学杂志,2021,28(1):1-12.
[8] 郑筱萸,中药新药临床研究指导原则[M].北京：中国医药科技出版社,2002:378- 383.
[9] 李宏烨,李慧菊,付志博,等.参芪肌痿颗粒治疗重症肌无力临床疗效观察[J].河北中 医,2020,42(7):1017-1020.
[10] Janssen MF,Dewilde S,Wolfe GI,et al.Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets.J Neurol Sci.2024;463:123135.
[11] 宋健,曾进浩,刘友章,等.国医大师邓铁涛从脾论治重症肌无力临床经验[J].陕西 中医,2022,43(12):1774-1777.
[12] 刘小斌.国医大师邓铁涛诊治重症肌无力经验的学术传承与发展[J].广州中医药大 学学报,2024,41(10):2518-2525.
[13] 张会永,冷锦红,谢伟峰,等.张静生治疗重症肌无力临证经验与用药分析[J].中华 中医药学刊,2020,38(12):27-30.
[14] Weng S,Huang L,Cai B,et al.Astragaloside IV ameliorates experimental autoimmune myasthenia gravis by regulating CD4 + T cells and altering gut microbiota.Chin Med.2023;18(1):97.
[15] He X,Li Y,Chen J,et al.Ginsenoside Rg1 Attenuates Muscle Atrophy in Hyperglycemic Conditions, Inactivity and Protein Deprivation Models via AKT/mTOR Pathway Activation.Curr Mol Med.2025.
[16] Ran P,Jiang F,Pan L,et al.Polysaccharide from Atractylodes macrocephala Koidz.alleviates pyrotinib-induced diarrhea through regulating cAMP/LKB1/AMPK/CFTR pathway and restoring gut microbiota and metabolites.Int J Biol Macromol.2025;308:142512.
[17] 沈洁,陈园园,董云,等.基于数据挖掘探讨中医药治疗眼肌型重症肌无力的用药规 律[J].中国中医药科技,2023,30(5):1034-1037.
[18]郑鸿铭,胡芝凡,黄梦芬,等.基于数据挖掘和网络药理学研究中药复方治疗重症肌无力的用药规律及作用机制[J].天津中医药,2024,41(3):372-385.
Copyright © 2026 李宏烨, 李树君, 常振刚, 付志博, 田得雨, 周红飞, 聂康, 刘虎, 王金霞, 陈沙沙, 周小婷, 李慧菊, 张静娟
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License